Table 1.
Characteristics of patients with ABMR according to two types: preexisting DSA and de novo DSA
| Characteristics | All Patients | Preexisting Anti-HLA DSA ABMR | De Novo Anti-HLA DSA ABMR | P Value | |||
|---|---|---|---|---|---|---|---|
| n | n=205 | n | n=103 | n | n=102 | ||
| Recipient | |||||||
| Age, yr, mean (SD) | 205 | 47.16 (15.39) | 103 | 47.75 (13.00) | 102 | 46.56 (17.52) | 0.53 |
| Men, n (%) | 205 | 118 (57.56) | 103 | 46 (44.66) | 102 | 72 (70.59) | <0.001 |
| ESRD causes, n (%) | 205 | 103 | 102 | ||||
| Glomerulonephritis | 75 (36.59) | 28 (27.18) | 47 (46.08) | ||||
| Diabetes | 16 (7.80) | 6 (5.83) | 10 (9.80) | ||||
| Polycystic kidney disease | 10 (4.88) | 3 (2.91) | 7 (6.86) | ||||
| Tubulo-interstitial disease | 29 (14.15) | 24 (23.30) | 5 (4.90) | ||||
| Hypertension | 14 (6.83) | 7 (6.80) | 7 (6.86) | ||||
| Unknown | 43 (20.97) | 29 (28.16) | 14 (13.73) | ||||
| Other | 18 (8.78) | 6 (5.82) | 12 (11.77) | <0.001 | |||
| Donor | |||||||
| Age, yr, mean (SD) | 203 | 45.57 (17.15) | 103 | 48.06 (14.56) | 100 | 43.01 (19.20) | 0.04 |
| Men, n (%) | 203 | 109 (53.69) | 103 | 57 (55.34) | 100 | 52 (52.00) | 0.37 |
| DD, n (%) | 204 | 158 (77.45) | 103 | 93 (90.29) | 101 | 65 (64.36) | <0.001 |
| Immunology at the time of transplant | |||||||
| HLA class of anti-HLA DSA, n | 103 | 103 | |||||
| Immunodominant class 1 | 49 | 49 | — | ||||
| Immunodominant class 2 | 54 | 54 | — | ||||
| DSA MFI, median [IQR] | 4500 [1862–10,210] | 4500 [1862–10,210] | — | ||||
| Treatment at the time of transplant, n (%) | |||||||
| Steroids | 205 | 194 (94.63) | 103 | 103 (100) | 102 | 91 (89.22) | <0.001 |
| Thymoglobulin | 205 | 111 (54.15) | 103 | 70 (67.96) | 102 | 41 (40.20) | <0.001 |
| Plasmapheresis | 205 | 18 (8.78) | 103 | 18 (17.48) | 102 | 0 | <0.001 |
| Anti-CD20 therapy | 205 | 20 (9.76) | 103 | 20 (19.42) | 102 | 0 | <0.001 |
| IVIG | 205 | 69 (33.66) | 103 | 61 (59.22) | 102 | 8 (7.84) | <0.001 |
| Baseline immunosuppression, n (%) | 205 | 103 | 102 | ||||
| Tacrolimus | 131 (63.90) | 89 (86.41) | 42 (41.18) | <0.001 | |||
| Cyclosporin | 70 (34.15) | 15 (14.56) | 55 (53.92) | <0.001 | |||
| Sirolimus | 2 (0.98) | 0 | 2 (1.96) | 0.25 | |||
| Follow-up, yr, mean (SD) | 205 | 4.13 (2.52) | 103 | 4.71 (2.42) | 102 | 3.55 (2.50) | 0.001 |
| Graft loss, n (%) | 205 | 86 (41.95) | 103 | 30 (29.13) | 102 | 56 (54.90) | <0.001 |
—, patients in the de novo DSA ABMR have no DSA at the time of transplant; MFI, mean fluorescence intensity.